Nitromemantine | 765890-91-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: Nitromemantine
• 英文别名: (3-amino-5,7-diethyl-1-adamantyl) nitrate
• CAS: 765890-91-3
• 化学式: C14H24N2O3
• 分子量: 268.35
• InChiKey: SENUTBBWBZZNRT-UHFFFAOYSA-N

物化性质

• 沸点：
  331.8±21.0 °C(Predicted)
• 密度：
  1.18±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  81.1
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• Methods and compositions for treating neurological conditions
  申请人：Lipton Stuart A.

  公开号：US11529319B2

  公开（公告）日：2022-12-20

  Disclosed herein are methods for treating juvenile onset neurological conditions, such as autism (ASD), intellectual disability, or epilepsy, with an inhibitor of N-methyl-D-aspartate receptor (NMDAR). The inhibitor may be NitroSynapsin or a derivative thereof.

  本文公开了用N-甲基-D-天冬氨酸受体（NMDAR）抑制剂治疗幼年发病的神经系统疾病，如自闭症（ASD）、智力障碍或癫痫的方法。抑制剂可以是NitroSynapsin或其衍生物。
• NMDA RECEPTOR ANTAGONISTS FOR TREATING GAUCHER DISEASE
  申请人：Yeda Research and Development Co. Ltd.

  公开号：US20170273917A1

  公开（公告）日：2017-09-28

  The present invention provides pharmaceutical compositions comprising at least one NMDA receptor antagonist for use in treating neuropathic forms of Gaucher Disease (nGD).
• AMINOADAMANTYL NITRATE COMPOUNDS AND THEIR USE TO TREAT CNS DISORDERS
  申请人：Panorama Research, Inc.

  公开号：US20200377444A1

  公开（公告）日：2020-12-03

  The present disclosure provides adamantyl compounds having one or more amine groups and one or more nitrate groups. The aminoadamantyl nitrate compounds can be used to treat disorders of the central nervous system, including neurodegenerative and non-neurodegenerative diseases.
• METHODS AND COMPOSITIONS FOR TREATING NEUROLOGICAL CONDITIONS
  申请人：LIPTON Stuart A.

  公开号：US20200368177A1

  公开（公告）日：2020-11-26

  Disclosed herein are methods for treating juvenile onset neurological conditions, such as autism (ASD), intellectual disability, or epilepsy, with an inhibitor of N-methyl-D-aspartate receptor (NMDAR). The inhibitor may be NitroSynapsin or a derivative thereof.
• COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE
  申请人：University of Virginia Patent Foundation

  公开号：US20210002650A1

  公开（公告）日：2021-01-07

  Provided are methods for treating Alzheimer's disease (AD), which in some embodiments can include administering to a subject in need thereof a composition that includes an inhibitor of an Aβ oligomer (AβO) biological activity. Also provided are methods for inhibiting development and/or progression of at least one symptom associated with AD, methods for inhibiting neuronal cell cycle re-entry (CRR), methods for inhibiting Aβ oligomer (AβO) biological activity, methods for inhibiting Aβ oligomer (AβO)-stimulated activation of calcium-calmodulin-dependent protein kinase II (CaMKII) biological activity, and methods for inhibiting calcium influx-induced excitotoxic neuronal death. In some embodiments, the inhibitor of the AβO biological activity or the inhibitor of N-methyl-D-aspartate receptor (NMDAR) signaling includes a small molecule inhibitor, an inhibitory nucleic acid, a calcium chelator, or any combination thereof. Also provided are methods for treating subjects who are pre-symptomatic for AD with inhibitors of AβO and/or NMDAR biological activities.